ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE TUMORS

Clinical trials for ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE TUMORS explained in plain language.

Never miss a new study

Get alerted when new ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE TUMORS trials appear

Sign up with your email to follow new studies for ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Last-Hope drug access opens for rare cancer patients

Disease control AVAILABLE

This program provides access to the drug ceritinib for patients with ALK-positive cancers, including lung cancer and pediatric tumors, when no other treatments are available. It is for people who cannot join regular clinical trials and have serious or life-threatening conditions.…

Matched conditions: ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE TUMORS

Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Mar 25, 2026 14:09 UTC

ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE TUMORS

Get alerted when new ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE TUMORS trials appear

Last-Hope drug access opens for rare cancer patients